|
|
Vol. 27.18 – 26 October, 2026
|
|
|
|
|
|
|
|
|
Investigators analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel from 580 patients with non-Hodgkin lymphoma across multiple clinical trials with long-term follow-up. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
The authors developed NK cell-targeted lipid nanoparticles (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Systemic delivery of CAR mRNA using NtLNPs generates CAR NK cells in vivo.
[Nature Biotechnology]
|
|
|
|
|
|
Through single cell RNA-sequencing of tumors at the time of progression from CART19, investigators showed that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction. [Blood]
|
|
|
|
|
|
Scientists developed PrimeCAR, a two-day manufacturing strategy combining low-intensity anti-CD3 priming with IL-7 and IL-21. Functionally, PrimeCAR cells demonstrated enhanced expansion, persistence, and durable antitumor activity in xenograft models.
[Cell Stem Cell]
|
|
|
|
|
|
To identify intrinsic persistence regulators in a TCR-based context, researchers performed an in vivo CRISPR activation screen in synthetic T cell receptor and antigen receptor T cells and identified the noncanonical NF-κB axis, with RELB as the top hit.
[Cellular & Molecular Immunology]
|
|
|
|
|
|
Investigators compared conventional CAR-T cells, systemic T cell engagers, TCE-secreting (STAb)-T cells, and dual-targeting CAR–STAb-T cells in immunocompetent mouse models of high-grade glioma.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
Scientists identified B7-H3 as a favorable target antigen for CAR T cell therapy of glioblastoma and developed a B7-H3 targeting CAR T cell. [JCI Insight]
|
|
|
|
|
|
|
|
Investigators summarize the clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials and discuss three waves shaping next-generation development [Cancer Cell]
|
|
|
|
|
|
The authors summarize the biological rationale, clinical evidence, safety considerations, and resistance mechanisms of T cell receptor–engineered T cell therapy in solid tumors and discuss future directions to optimize their therapeutic potential. [Annual Review of Medicine]
|
|
|
|
|
|
|
|
Alex’s Lemonade Stand Foundation has funded 12 Innovation Grants to help researchers pursue bold ideas that could change the future of childhood cancer. Researchers are exploring new ways to overcome treatment resistance and uncover vulnerabilities that could lead to new therapies.
[Alex’s Lemonade Stand Foundation for Childhood Cancer]
|
|
|
|
|
|
Anixa Biosciences, Inc. announced that it has completed dosing of the fifth cohort in its ongoing Phase I, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. [Anixa Biosciences, Inc. (BioSpace)]
|
|
|
|
|
|
|
|
January 25-27, 2027 Keystone, Colorado, United States
|
|
|
|
|
|
|
|
|
|
|
Boston University Medical Campus – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Schulich School of Medicine & Dentistry, Western University – London, Ontario, Canada
|
|
|
|
|
|
|
University of Maryland School of Medicine – Maryland, Baltimore, United States
|
|
|
|
|
|
|
St Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
University of California Los Angeles – Los Angeles, California, United States
|
|
|
|
|
|